Tuesday , October 19 2021

Alembic Pharmaceuticals surges with its JV getting EIR from USFDA for facility at Karkhadi

Alembic Pharmaceuticals is currently trading at Rs. 549.05, up by 6.65 points or 1.23% from its previous closing of Rs. 542.40 on the BSE.

The scrip opened at Rs. 547.85 and has touched a high and low of Rs. 560.30 and Rs. 541.60 respectively. So far 494 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.

Last one week high and low of the scrip stood at Rs. 572.90 and Rs. 540.00 respectively. The current market cap of the company is Rs. 10308.99 crore.

The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.98% and 12.05% respectively.

Aleor Dermaceuticals (Aleor), a 60:40 Joint Venture (JV) between Alembic Pharmaceuticals (Alembic) and Orbicular Pharmaceutical Technologies (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor’s Formulation Facility at Karakhadi, Gujarat, India during the period from February 04, 2019 to February 08, 2019.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'